Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
livmoniplimab
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Livmoniplimab is a humanized monoclonal antibody targeting the cell surface protein GARP (glycoprotein A repetitions predominant, also known as LRRC32), which acts as an activator of transforming growth factor beta (TGF-beta). It is being developed primarily for the treatment of advanced cancers, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), urothelial carcinoma, and other solid tumors. Livmoniplimab functions by inhibiting TGF-beta signaling in the tumor microenvironment, thereby enhancing anti-tumor immune responses. The drug is often studied in combination with budigalimab (ABBV-181), a PD-1 inhibitor, to further augment immunotherapeutic effects. Livmoniplimab was originally discovered by Catholic University of Louvain and Ludwig Institute for Cancer Research and is currently being developed by AbbVie[2][3][4][6].
- Other names
- livmoniblug
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on livmoniplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on livmoniplimab.